UNSPSC 51142545: Brasofensine maleate

This classification denotes the brasofensine form of an antiparkinsonian agent with the molecular formula C16H20Cl2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1YP2S94RVH, chemically known as 3-beta-(3,4-dichlorophenyl)-1-alpha-h, 5-alpha-h-tropane-2-alpha-carboxaldehyde (e)-(o-methyloxime). but more generally known as brasofensine, which bears US NIH Compound Identifier 9554198. Brasofensine most often comes in base, maleate, and sulfate forms.

UNSPSC 51142545 Brasofensine maleate is a Commodity code that in recent state and local procurement activity covers the supply of pharmaceutical products and related health-system supplies to county health departments, state health agencies, and cooperative purchasing alliances. However, the recent opportunities posted under this code show a mismatch: the three opportunities on record involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs and market intelligence (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance). None of these directly address brasofensine maleate or pharmaceuticals in that specific category. The issuing bodies include a county health department (Seminole County), a state health and human services commission (Texas HHS), and a multistate cooperative purchasing alliance administered by a state procurement office (MMCAP through Minnesota Department of Administration). The code appears to serve a broad range of pharmaceutical procurement across different government tiers and structures.

Activity is spread across Florida, Texas, and Minnesota, with the most recent opportunity being the Seminole County naloxone procurement (IFB 60459723LAS, due July 26, 2023). The Texas HHS RFI (HHS0017013) posted April 3, 2026 represents exploratory market research for direct-to-manufacturer prescription programs rather than a formal competitive bid. The Minnesota MMCAP RFP (S1070000015802), posted January 20, 2026 with responses due March 26, 2026, seeks manufacturers to supply generic pharmaceuticals and OTC products through authorized wholesalers to participating state and local government facilities, including Oregon. Given the scope mismatch between the code's nominal designation and the actual solicitations posted under it, the code shows limited relevant recent activity for brasofensine maleate specifically; practitioners should verify code assignment when pursuing pharmaceutical opportunities in this family.